Scientia Advisors in the News
Boston Globe--For drug makers, a shot in the arm: The quest for an H1N1 vaccine has been good business for some firms
In this article, Robert Weisman delves into impact of the H1N1 vaccine push has had on vaccine-makers such as Novartis. He points out that in addition to the actual revenue garnered from the vaccine, the headway made in developing new research and streamlining of the production of vaccines, either by organic growth or acquisition, will be beneficial to the companies in future vaccine development. Scientia Advisors' global vaccines market projections, from $16 billion in 2007 to $35 billion in 2014, is cited in the article. Scientia Advisors' Managing Partner, Harry Glorikian was also quoted in the article pointing out the potential opportunity for vaccine makers in China which is planning on a national vaccine program.SCIENTIA ADVISORS, LLC | info@scientiaadv.com
55 Cambridge Parkway, Suite 300E, Cambridge MA 02142 | Phone: 617-299-3000 | Fax: 617-812-0315
© 2012 Scientia Advisors LLC
